Specialty Pharmacy

Investigators aim to develop cellular models to mimic the biological processes responsible for the onset of multiple sclerosis.

Slow walking speed associated with higher risk of poor outcomes for older patients with blood cancers.

Top news of the day from across the health care landscape.

Genentech is seeking approval for rituximab (Rituxan) with glucocorticoids for pediatric patients with granulomatosis with polyangiitis and microscopic polyangiitis.

Patients with hemophilia A across all age groups reported stabilization or improvement of quality of life and high treatment satisfaction.

Top news of the day from across the health care landscape.

Pembrolizumab is now indicated for use as a first-line monotherapy treatment for metastatic or unresectable recurrent head and neck squamous cell carcinoma.

An unhealthy microbiome caused by chronic antibiotic treatment could result in long-term inflammation within the tissue and tumor environment.

Top news of the day from across the health care landscape.

Polatuzumab vedotin-piiq (Polivy) is a first-of-its-kind anti-CD76b antibody-drug conjugate used in combination with bendamustine plus rituximab (Rituxan) for previously-treated diffuse large B-cell lymphoma.

Ali McBride, PharmD, BCOP, president of the Association of Community Cancer Centers, discusses how pharmacists can assist in adverse event management during the American Society of Clinical Oncology Annual Meeting in Chicago, IL

Ali McBride, PharmD, BCOP, president of the Association of Community Cancer Centers, discusses the key takeaways from the ASCO 2019 meeting and the important information that pharmacists should be aware of during the American Society of Clinical Oncology Annual Meeting in Chicago, IL

Zolgensma is the first gene therapy indicated for the treatment of children with spinal muscular atrophy.

Expanded mental health care at HIV clinics across the United States could help in reaching the goal of viral suppression among 90% of the population.

Top news of the day from across the health care landscape.

Many different strategies to achieve sustained virologic remission in HIV are being evaluated.

Top news of the day from across the health care landscape.

Top news of the week from Specialty Pharmacy Times.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Obesity may increase severity of disability in patients with relapsing-remitting multiple sclerosis.

Top news of the day from across the health care landscape.

Breast cancers with somatic or germline BRCA 1/2 mutations may not be as responsive to checkpoint inhibitors as previously thought.

The FDA has accepted and set action dates for the luspatercept (Celgene and Acceleron) Biologic License Application.

Top news of the day from across the health care landscape.

Ginah Nightingale, PharmD, BCOP, associate professor of pharmacy practice at the Jefferson College of Pharmacy at Thomas Jefferson University discusses how pharmacist-led interventions help to reduce adverse events associated with polypharmacy in geriatric patients during the American Society of Clinical Oncology Annual Meeting in Chicago, IL.

Galcanezumab-gnlm (Emgality, Eli Lilly) is the first calcitonin gene-related peptide antibody approved for both migraine and episodic cluster headache in adults.

Jorge Eduardo Cortes, MD, Deputy Chair and Professor of Medicine in the Department of Leukemia at MD Anderson Cancer Center in Houston, Texas, references the ENESTop 192-week study results in which treatment-free remission was achieved in patients with chronic myeloid leukemia in chronic phase after stopping second-line nilotinib.

Ginah Nightingale, PharmD, BCOP, associate professor of pharmacy practice at the Jefferson College of Pharmacy at Jefferson University, discusses how pharmacists can counsel geriatric patients who may be taking multiple medications for chronic illnesses during the American Society of Clinical Oncology Annual Meeting in Chicago, IL.

The Impassion130 trial evaluated whether atezolizumab plus nanoparticle albumin-bound paclitaxel increased overall survival in patients with triple negative breast cancer when compared to chemotherapy alone.

During the American Society of Clinical Oncology Annual Meeting in Chicago, IL, Ali McBride, PharmD, BCOP, president of the Association of Community Cancer Centers, discusses how growth in the oncology space will affect how pharmacists practice.